[DOI] [PMC free article] [PubMed] [Google Scholar] 126.Durand P., Prost M., Blache D
Menopause has also been suggested as a factor that increases the probability of maintaining normoprolactinemia after dopamine agonist therapy is stopped.18 Unless there is evidence of growth of a prolactinoma or related symptoms, such as headache, there is no indication to continue dopamine agonist therapy after menopause.18 There are no significant differences in age, sex, initial dopamine agonist dose or length of treatment between those with continued normoprolactinemia and those with recurrence of hyperprolactinemia.18 We suggest that the dopamine agonist dose be decreased after 2 or 3 years of normal prolactin levels and that therapy be stopped if the prolactin levels remain unchanged after 1 year at the reduced dose
J Clin Psychopharmacol 26:524529 Pross N, Patat A, Vivet P, Bidaut M, Fauchoux N (2015) Pharmacodynamic interactionsof a solid formulation of sodium oxybate and ethanol in healthy volunteers
That is one of the most important practical distinctions in plain-language comparisons
Managing missed doses appropriately is important for maintaining therapeutic benefits while avoiding adverse effects from irregular dosing patterns
Peptides like Retatrutide can lose potency if left at room temperature for extended time periods
/assets/images/provider/photos/2775905.jpeg)
